

Fisher Broyles

Name: Maura L. Burke

Email: maura.burke@fisherbroyles.com

Direct: +1.215.398.5916

Mobile: +1.267.237.2746

Office: Wilmington, Philadelphia

Practice Areas: Appellate; Civil Pretrial & Trial Services; Commercial Litigation; Corporate Governance; Litigation & Risk Management; White Collar Litigation and Investigations

Bar Admissions: Delaware; Pennsylvania; New Jersey

Education: Villanova University School of Law, J.D. 2009; George Washington University, B.A. 2001

Experience: Fox Rothschild LLP

Maura is a Delaware licensed attorney and experienced litigator who handles a wide range of commercial litigation matters, including contractual and business disputes, legal malpractice, corporate governance, and directors' and officers' liability matters. In addition, she has experience managing complex bankruptcy litigation, representing bankruptcy trustees, and prosecuting and defending against adversary claims. Maura also counsels public utilities on regulatory and litigation matters, and has appeared before the Pennsylvania Public Utility Commission to secure base rate increases, change of control approvals, and certificates of public convenience. She also has extensive experience representing white collar defendants in state and federal investigations.

Representative Transactions

- Won \$420 million judgment against FDIC, affirmed by the Third Circuit Court of Appeals
- Secured \$373 million settlement against the United States in tax litigation before the Court of Federal Claims
- Fast-tracked Pennsylvania Public Utility Commission regulatory approval of the change of control of a steam utility that included \$770 million in associated financing
- Secured rate relief totaling an annualized amount of \$3.3 Million for steam utility
- Successfully defended global pharmaceutical company against claims for contractual indemnification arising from underlying Lanham Act litigation
- Successfully defended drug manufacturer in statewide coordinated opioid litigation
- Successfully defended a global pharmaceutical company against claim for breach of a license and supply agreement by generic pharmaceutical manufacturer